首頁 > 市場調查報告書 > 製藥

生技設備基因治療學和RNAi

市場調查報告書

商品編碼

1572521

細胞活力檢測市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cell Viability Assays Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 265 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球細胞活力檢測市場價值為 17 億美元，預計在預測期內複合年成長率為 8.5%。這種成長是由精準醫學的日益普及和生物技術的進步所推動的，從而刺激了對可靠和準確的細胞活力測試的需求。此外，癌症和心血管疾病等慢性疾病的盛行率不斷上升，凸顯了對高效藥物發現過程和新療法的需求，而這在很大程度上依賴於細胞活力測定。

該市場受益於臨床試驗和早期藥物測試的激增，以及細胞和分子生物學研究活動的擴大。研究和開發資金的增加，加上自動化分析和高通量篩選等先進技術的採用，進一步推動了市場的擴張。

細胞活力測定在毒理學、藥物開發和細胞生物學等各種生物醫學研究領域中至關重要，因為它們評估細胞在特定環境下的生存和功能能力。這些測定對於確定化學物質、治療或環境變化對細胞健康的影響至關重要。

市場根據產品、應用、最終用戶和地區進行細分。

2023 年，由於日常研究必不可少的試劑、檢測試劑盒和微孔板的頻繁使用，消耗品領域佔據了 62.4% 的市場佔有率。在應用方面，由於對幹細胞治療的需求不斷成長，幹細胞研究的價值為7.133億美元。對再生醫學的日益關注以及幹細胞在疾病建模和個人化醫療中的廣泛應用也有助於該細分市場的成長。

在最終用戶中，生物製藥和製藥公司預計將以 8.6% 的複合年成長率成長，因為它們在藥物開發中嚴重依賴細胞活力測定。監管要求和研發方面的大量投資進一步支撐了該領域的主導地位。

2023 年，北美細胞活力檢測市場規模達 6.96 億美元，預計複合年成長率為 8.3%。光是美國在先進技術、支持性監管架構和大量研究投資的推動下，2023 年的銷售額就達到 6.41 億美元，預計到 2032 年將達到 13 億美元。美國市場受益於其採用尖端技術，提高了細胞活力測試的準確性和效率。

產業生態系統分析
產業影響力
- 成長動力
  - 增加藥物發現和開發
  - 基於細胞的檢測的進展
  - 加強幹細胞研究
- 產業陷阱與挑戰
  - 先進檢測和儀器的高成本
  - 技術複雜，需要專業知識
成長潛力分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
耗材
- 檢測試劑盒
  - 四唑還原測定試劑盒
    - MTT檢測
    - MTS 檢測
    - XTT 檢測
    - 其他四唑還原測定試劑盒
  - 刃天青細胞活力測定試劑盒
  - Calcein-AM 細胞活力測定試劑盒
  - 其他檢測試劑盒
- 試劑
- 微孔板
儀器儀表
- 分光光度計
- 流式細胞儀
- 自動細胞計數器
- 顯微鏡檢查
- 細胞成像和分析系統

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
幹細胞研究
藥物發現與開發
基礎研究
臨床和診斷應用
其他應用

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
生物製藥和製藥公司
CRO 和 CMO
學術及研究機構
診斷實驗室

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abcam plc
Abnova Corporation
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioTek Instruments, Inc. (Agilent Technologies, Inc.)
Biotium, Inc.
Canvax Biotech S.L.
Creative Bioarray, Inc.
Danaher Corporation
Geno Technology, Inc.
GE Healthcare Technologies, Inc.
Merck KGaA
PerkinElmer, Inc.
Promega Corporation
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 10906

The Global Cell Viability Assays Market was valued at USD 1.7 billion in 2023 and is projected to grow at a CAGR of 8.5% over the forecast period. This growth is driven by the increased adoption of precision medicine and advancements in biotechnology, fueling the demand for reliable and accurate cell viability testing. In addition, the rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, underscores the need for efficient drug discovery processes and novel therapeutics, which heavily rely on cell viability assays.

The market benefits from a surge in clinical trials and early-stage drug testing, alongside expanding research activities in cellular and molecular biology. Increased funding for research and development, coupled with the adoption of advanced technologies like automated assays and high-throughput screening, further propels the market expansion.

Cell viability assays are essential in various biomedical research fields, including toxicology, drug development, and cell biology, as they assess a cell's ability to survive and function under specific circumstances. These assays are critical for determining the effects of chemicals, treatments, or environmental changes on cell health.

The market is segmented based on Product, Application, End-user, and Region.

In 2023, the consumables segment dominated with a 62.4% market share, driven by the frequent use of reagents, assay kits, and microplates, which are essential for routine research. In terms of applications, stem cell research was valued at USD 713.3 million, driven by the rising demand for stem cell-based treatments. The growing focus on regenerative medicine and the broad applications of stem cells in disease modeling and personalized medicine also contribute to the segment growth.

Among end-users, biopharmaceutical and pharmaceutical companies are expected to grow at 8.6% CAGR, as they heavily rely on cell viability assays in drug development. Regulatory requirements and substantial investments in research and development further support this segment's dominance.

North America accounted for USD 696 million in the cell viability assays market in 2023, with a projected growth rate of 8.3% CAGR. The U.S. alone accounted for USD 641 million in 2023 and is expected to reach USD 1.3 billion by 2032, driven by advanced technology, a supportive regulatory framework, and significant investments in research. The U.S. market benefits from its adoption of cutting-edge technologies, enhancing the accuracy and efficiency of cell viability testing.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increased drug discovery and development
  - 3.2.1.2 Advancements in cell-based assays
  - 3.2.1.3 Increasing stem cell research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced assays and instruments
  - 3.2.2.2 Technical complexity requiring expertise
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
- 5.2.1 Assay kits
  - 5.2.1.1 Tetrazolium reduction assay kits
    - 5.2.1.1.1 MTT assays
    - 5.2.1.1.2 MTS assays
    - 5.2.1.1.3 XTT assays
    - 5.2.1.1.4 Other tetrazolium reduction assay kits
  - 5.2.1.2 Resazurin cell viability assay kits
  - 5.2.1.3 Calcein-AM cell viability assay kits
  - 5.2.1.4 Other assay kits
- 5.2.2 Reagents
- 5.2.3 Microplates
5.3 Instruments
- 5.3.1 Spectrophotometers
- 5.3.2 Flow cytometers
- 5.3.3 Automated cell counters
- 5.3.4 Microscopy
- 5.3.5 Cell imaging and analysis systems

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Stem cell research
6.3 Drug discovery and development
6.4 Basic research
6.5 Clinical and diagnostic applications
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Biopharmaceutical and pharmaceutical companies
7.3 CROs and CMOs
7.4 Academic and research institutes
7.5 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa